SCHOTT Pharma Reaffirms FY 24 Outlook, Anticipates Slower Growth in FY 25 Due to Reduced Syringe Demand

SCHOTT Pharma AG & Co. KGaA, a leader in pharmaceutical packaging and delivery systems, has released its fiscal half-year results ending March 2024, showing a revenue increase to EUR 489 million, up 9% at constant currencies compared to the previous year. However, despite these positive figures, the company foresees a tempered growth forecast for fiscal year 2025, largely due to decreased demand for syringes from a major customer.

The company reported an EBITDA of EUR 134 million with a margin of 27.4% at constant currencies. It has confirmed its revenue growth projection of 9 to 11% for FY 24 and maintains a stable EBITDA margin outlook. The lower expected revenues from the syringe segment in FY 25, however, are anticipated to moderately impact overall growth and margin expansion in that period. SCHOTT Pharma attributes this expected downturn to broader industry shifts and specific customer behavior changes, including ongoing stock optimizations.

Despite the near-term challenges, SCHOTT Pharma remains optimistic about the long-term market fundamentals and continues to invest in strategic initiatives focusing on innovation and expansion within its pharmaceutical systems divisions. The company confirms adherence to its mid-term financial goals, expecting to rebound to a double-digit annual growth rate and aiming for an EBITDA margin in the low 30% range. Full financial details for Q2 2024 will be made available on June 27, 2024.